HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>FAK inhibitors’ R&amp;D is not smooth.The breakthrough in FAK clinical protocol lies in the possibility of finding new application scenarios, such as the potential for combination with various anticancer drugs.</li>
<li>If ifebemtinib can be successfully approved for 2-3 core indications (e.g. PROC, NSCLC) and enter medical insurance smoothly, its sales peak in the China market may reach RMB2-3 billion.</li>
<li>Post-Money valuation after Series C Financing was USD306 million. The issuance valuation of InxMed may be given a certain premium on top of Series C valuation, such as US$350-500 million.</li>
</ul>


FAK inhibitors’ R&amp;D is not smooth.The breakthrough in FAK clinical protocol lies in the possibility of finding new application scenarios, such as the potential for combination with various anticancer drugs.
If ifebemtinib can be successfully approved for 2-3 core indications (e.g. PROC, NSCLC) and enter medical insurance smoothly, its sales peak in the China market may reach RMB2-3 billion.
Post-Money valuation after Series C Financing was USD306 million. The issuance valuation of InxMed may be given a certain premium on top of Series C valuation, such as US$350-500 million.


Pre-IPO InxMed - The Pipeline and the Outlook

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

InxMed (IXM HK)

Pre-IPO InxMed - The Pipeline and the Outlook

Breakthrough in FAK inhibitors clinical protocol hinges on new application scenario such as drug combination.IPO valuation may be given a certain...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pre-IPO InxMed - The Pipeline and the Outlook

​Breakthrough in FAK inhibitors clinical protocol hinges on new application scenario such as drug combination.IPO valuation may be given a certain...

Xinyao (Criss) Wang

Breakthrough in FAK inhibitors clinical protocol hinges on new application scenario such as drug combination.IPO valuation may be given a certain...